Literature DB >> 2379394

Ketamine by continuous infusion for sedation in the pediatric intensive care unit.

J D Tobias1, L D Martin, R C Wetzel.   

Abstract

ICU physicians generally rely on either narcotics or benzodiazepines to provide analgesia and sedation. We describe five patients in whom ketamine administered as a bolus dose of 0.5 to 1.0 mg/kg, followed by a continuous infusion of 10 to 15 micrograms/kg.min, provided effective sedation and analgesia without significantly compromising cardiorespiratory function. Four of these patients previously experienced deleterious cardiorespiratory effects from either benzodiazepines or narcotics. In three patients who were breathing spontaneously, PaCO2 remained less than 44 torr during the ketamine infusion. With ketamine, no reduction in mean arterial pressure from baseline was noted in any patient. As with any form of iv anesthesia, ketamine can have cardiorespiratory side-effects; therefore, the means to manage these effects should be readily available.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2379394     DOI: 10.1097/00003246-199008000-00004

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  9 in total

Review 1.  Sedation and analgesia in paediatric intensive care units: a guide to drug selection and use.

Authors:  J D Tobias
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

2.  Sedating patients in intensive care units.

Authors:  M S Mikhail; D Thangathurai
Journal:  West J Med       Date:  1992-11

3.  Continuous infusion of ketamine in mechanically ventilated children with refractory bronchospasm.

Authors:  M Z Youssef-Ahmed; P Silver; L Nimkoff; M Sagy
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

4.  Safety and Utility of Continuous Ketamine Infusion for Sedation in Mechanically Ventilated Pediatric Patients.

Authors:  Amy L Heiberger; Surachat Ngorsuraches; Gokhan Olgun; Lisa Luze; Caitlin Leimbach; Holly Madison; Saquib A Lakhani
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Nov-Dec

5.  Ketamine alters the neurogenesis of rat cortical neural stem progenitor cells.

Authors:  Chaoxuan Dong; Cynthia R Rovnaghi; K J S Anand
Journal:  Crit Care Med       Date:  2012-08       Impact factor: 7.598

6.  Extended Duration Ketamine Infusions in Critically Ill Children: A Case Report and Review of the Literature.

Authors:  Eszter Moore; Rebecca Mayes; Maura Harkin; Jamie L Miller; Peter N Johnson
Journal:  J Pediatr Intensive Care       Date:  2020-06-10

7.  Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine.

Authors:  Joe Brierley; Joseph A Carcillo; Karen Choong; Tim Cornell; Allan Decaen; Andreas Deymann; Allan Doctor; Alan Davis; John Duff; Marc-Andre Dugas; Alan Duncan; Barry Evans; Jonathan Feldman; Kathryn Felmet; Gene Fisher; Lorry Frankel; Howard Jeffries; Bruce Greenwald; Juan Gutierrez; Mark Hall; Yong Y Han; James Hanson; Jan Hazelzet; Lynn Hernan; Jane Kiff; Niranjan Kissoon; Alexander Kon; Jose Irazuzta; Jose Irazusta; John Lin; Angie Lorts; Michelle Mariscalco; Renuka Mehta; Simon Nadel; Trung Nguyen; Carol Nicholson; Mark Peters; Regina Okhuysen-Cawley; Tom Poulton; Monica Relves; Agustin Rodriguez; Ranna Rozenfeld; Eduardo Schnitzler; Tom Shanley; Saraswati Kache; Sara Skache; Peter Skippen; Adalberto Torres; Bettina von Dessauer; Jacki Weingarten; Timothy Yeh; Arno Zaritsky; Bonnie Stojadinovic; Jerry Zimmerman; Aaron Zuckerberg
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

Review 8.  Advantages of ketamine in pediatric anesthesia.

Authors:  Alessandro Simonini; Etrusca Brogi; Marco Cascella; Alessandro Vittori
Journal:  Open Med (Wars)       Date:  2022-07-06

9.  Effects of continuous ketamine infusion on hemodynamics and mortality in critically ill children.

Authors:  Sojin Park; Ah Young Choi; Esther Park; Hyo Jung Park; Jaehyun Lee; Hukyoung Lee; JeongMee Kim; Joongbum Cho
Journal:  PLoS One       Date:  2019-10-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.